Christopher James Hoimes, DO
- Bladder Cancer
- Genitourinary Oncology
- High-Dose Interleukin-2 (HD IL-2)
- Kidney Cancer
- New Therapeutics
- Phase I Clinical Trials
- Prostate Cancer
- Testicular Cancers
Patient Satisfaction Reviews
4.7 out of 5
Patient Comments (5)
Reviewed On 12/29/2018
We work as a team to determine my treatment plan for *****. I feel that I have been given good information to make importanat health decisions, my concerns are taken seriously, and meetings are positive and realistic. I feel blessed to have come to Seidman for my*****treatments.
Reviewed On 12/15/2018
they all are very personable which is what I like in a professional. thank you
Reviewed On 12/10/2018
Reviewed On 11/18/2018
my experience was very good .
Reviewed On 8/19/2018
Doctor is very considerate and helpful.
- Medical Oncology - American Board of Internal Medicine
- Medical Oncology - American College of Osteopathic Internists
- Internal Medicine - American Board of Internal Medicine
Fellowship | Genitourinary Medical Oncology
Genitourinary Medical Oncology - Yale University School Of Medicine (2009 - 2010)
Fellowship | Medical Oncology
Medical Oncology - Yale University School Of Medicine (2006 - 2009)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Milton S Hershey Medical Center (2005 - 2006)
Residency | Internal Medicine
Internal Medicine - Milton S Hershey Medical Center (2002 - 2005)
Internship | Rotator
Rotator - Good Samaritan Hospital Medical Center (2001 - 2002)
Yale University (2015)
New York Institute Of Technology College Of Osteopathic Medicine (2001)
Suny Stony Brook University (1996)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Christopher James Hoimes did not disclose any Outside Relationships with Industry.